These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 22399309)

  • 1. Cardiovascular risk in rheumatic patients: the link between inflammation and atherothrombosis.
    Di Minno MN; Iervolino S; Lupoli R; Russolillo A; Coppola A; Peluso R; Scarpa R; Di Minno G
    Semin Thromb Hemost; 2012 Jul; 38(5):497-505. PubMed ID: 22399309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological management of inflammatory rheumatic conditions].
    Bannwarth B
    Therapie; 2011; 66(5):377-81. PubMed ID: 22031680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
    Avouac J; Allanore Y
    Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular disease in rheumatoid arthritis: disease and treatment interactions and their implications on treatment decisions.
    Sanders S; Geraci SA
    J Miss State Med Assoc; 2010 Mar; 51(3):75-80. PubMed ID: 20827876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Rheumatoid arthritis: a cardiovascular disease?].
    Daïen CI; Fesler P
    Ann Cardiol Angeiol (Paris); 2012 Apr; 61(2):111-7. PubMed ID: 21885031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-α blockade, cardiovascular outcomes, and survival in rheumatoid arthritis.
    Al-Aly Z; Pan H; Zeringue A; Xian H; McDonald JR; El-Achkar TM; Eisen S
    Transl Res; 2011 Jan; 157(1):10-8. PubMed ID: 21146146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database.
    Di Minno MN; Iervolino S; Zincarelli C; Lupoli R; Ambrosino P; Pizzicato P; Di Minno A; Pappone N; Peluso R
    Expert Opin Drug Saf; 2015; 14(12):1905-13. PubMed ID: 26618553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular outcomes and tumour necrosis factor antagonists in chronic inflammatory rheumatic disease: a focus on rheumatoid arthritis.
    Tocci G; Goletti D; Marino V; Matucci A; Milano GM; Cantini F; Scarpa R
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):55-61. PubMed ID: 27924645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammatory arthritis as a novel risk factor for cardiovascular disease.
    John H; Kitas G
    Eur J Intern Med; 2012 Oct; 23(7):575-9. PubMed ID: 22841864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rheumatic diseases as risk factors for cardiovascular disease].
    Nurmohamed MT; Voskuyl AE; van der Horst-Bruinsma IE; Dijkmans BA
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1921-4. PubMed ID: 16999275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease in inflammatory rheumatic diseases.
    Castañeda S; Nurmohamed MT; González-Gay MA
    Best Pract Res Clin Rheumatol; 2016 Oct; 30(5):851-869. PubMed ID: 27964792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
    Goodemote P; Jamieson B; Hoffman R
    J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
    [No Abstract]   [Full Text] [Related]  

  • 14. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
    Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relations of serum COMP to cardiovascular risk factors and endothelial function in patients with rheumatoid arthritis treated with methotrexate and TNF-α inhibitors.
    Hjeltnes G; Hollan I; Førre Ø; Wiik A; Lyberg T; Mikkelsen K; Agewall S
    J Rheumatol; 2012 Jul; 39(7):1341-7. PubMed ID: 22660798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases.
    Wendling D; Paccou J; Berthelot JM; Flipo RM; Guillaume-Czitrom S; Prati C; Dernis E; Direz G; Ferrazzi V; Ristori JM;
    Semin Arthritis Rheum; 2011 Dec; 41(3):503-10. PubMed ID: 21862108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Revision of the recommendations of the Commission on Pharmacotherapy of the German society for Rheumatology. Therapy with tumour necrosis factor blockers for inflammatory rheumatic illnesses].
    Manger B; Michels H; Nüsslein HG; Schneider M; Sieper J;
    Z Rheumatol; 2007 Feb; 66(1):72-5. PubMed ID: 17221253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TNF inhibitors in the treatment of arthritis.
    Lorenz HM
    Curr Opin Investig Drugs; 2000 Oct; 1(2):188-93. PubMed ID: 11249572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab.
    Spanakis E; Sidiropoulos P; Papadakis J; Ganotakis E; Katsikas G; Karvounaris S; Bizaki A; Kritikos H; Boumpas DT
    J Rheumatol; 2006 Dec; 33(12):2440-6. PubMed ID: 17014005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.
    Mason JC; Libby P
    Eur Heart J; 2015 Feb; 36(8):482-9c. PubMed ID: 25433021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.